RxDoctor Payments Data

Charles Beale, MD

Interventional Cardiology · Dartmouth, MANPI 1407146962

Payments from drug & device makers

What this record shows

23 manufacturers reported payments, led by Abbott at 31.6% of the total. Reporting peaked in 2019 at $6,171 and has fallen 63.8% since, to $2,232 in 2025.

$10,514in general payments, 2019–2025

Across 132 payments — averaging $79.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Edwards Lifesciences$3K
  • Medtronic$1K
  • Boston Scientific$1K
  • Inari Medical, Inc.$431
  • Novo Nordisk$283
  • plus $2K from 17 others

What the payments were for

  • Travel & lodging$5,12849%
  • Food & beverage$5,38551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,514 in reported general payments places this provider in the 60th percentile of 128 interventional cardiology providers in Massachusetts.

See all interventional cardiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$308,074
Medicare patients
750
Services billed
2,952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban202$214,503
EntrestoSacubitril/Valsartan38$38,921
Repatha SureclickEvolocumab18$25,695
JardianceEmpagliflozin28$23,961
XareltoRivaroxaban14$20,778
Metoprolol Succinate397$7,542
Amiodarone Hcl36$4,699
Atorvastatin Calcium251$3,303
Rosuvastatin Calcium77$2,767
Isosorbide Mononitrate ErIsosorbide Mononitrate112$2,509
Ranolazine ErRanolazine16$2,372
ClopidogrelClopidogrel Bisulfate114$2,000
Ezetimibe43$1,973
Prasugrel Hcl23$1,917
Carvedilol121$1,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$251$214,503202 claims
NovartisEntresto$217$38,92138 claims
Boehringer IngelheimJardiance$149$23,96128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 128 interventional cardiology providers in Massachusetts.

Other interventional cardiology in Dartmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →